Preclinical study of innovative peptides mimicking the tertiary structure of the α-helix B of erythropoietin

Авторы

DOI:

https://doi.org/10.3897/rrpharmacology.6.55385

Аннотация

Introduction: The aim of this study was to examine the effectiveness of innovative peptides obtained by addition of polypeptide motifs with antiaggregation activity (Arg-Gly-Asp, Lys-Gly-Asp and Pro-Gly-Pro) to a peptide mimicking the tertiary structure of the α-helix B of erythropoietin pHBSP (Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser).

Materials and methods: The cytoprotective activity of innovative peptides mimicking the tertiary structure of the α-helix B of erythropoietin at the doses of 5 μg/ml, 30 μg/ml and 50 μg/ml was studied on human endothelial cell cul­ture in a simulated oxidative stress. An ADMA-like model of preeclampsia was simulated in the experiment. The study was conducted in 260 female Wistar rats, weighing 250–300 g.

Results and discussion: Innovative peptides mimicking the tertiary structure of the α-helix B of erythropoietin retain their cytoprotective activity in a simulated oxidative stress in HUVEC cell culture at the doses of 5 μg/ml, 30 μg/ml, and 50 μg/ml. The compounds with laboratory codes P-αB1 and P-αB3 had the most pronounced cytoprotective activity. Administration of N-nitro-L-arginine-methyl ether to pregnant females for 7 days causes the morphofunctional changes similar to clinical changes in preeclampsia. The innovative peptide under laboratory code P-αB4 at the dose of 50 μg/kg mimicking the tertiary structure of the α-helix B of erythropoietin shows the most pronounced protective properties.

Conclusion: Innovative peptides mimicking the tertiary structure of the α-helix B of erythropoietin have a pronounced positive influence on the morphofunctional disorders in animals with ADMA-like preeclampsia.

Ключевые слова:

erythropoietin derivative, preeclampsia, endothelial dysfunction, microcirculation, placenta

Вклад авторов

Ivan V. Golubev, Belgorod State National Research University

External PhD studentof the Department of Pharmacology and Clinical Pharmacology.

Vladimir V. Gureev, Belgorod State National Research University

Doctor of Habilitated Medical Sciences, Associate Professor, Professor of the Department of Pharmacology and Clinical Pharmacology.

Mikhail V. Korokin, Belgorod State National Research University

Doctor Habilitated of Medical Sciences, Associate Professor, Professor of the Department of Pharmacology and Clinical Pharmacology.

Maria A. Zatolokina, Kursk State Medical University

Doctor Habilitated of Medical Sciences, Assistant Professor, Professor of the Department of Histology, Embryology, Cytology.

Elena V. Avdeeva, Kursk State Medical University

Doctor Habilitated of Biological Sciences, Professor of the Department of Normal Physiology.

Anastasia V. Gureeva, Kursk State Medical University

3-year student, Faculty of Medicine.

Il’ya S. Rozhkov, Kursk State Medical University

Postgraduate student, Department of Pharmacology and Clinical Pharmacology.

Elena A. Serdyuk, Belgorod State National Research University

Postgraduate student, Department of Pharmacology and Clinical Pharmacology.

Valeriya A. Soldatova, Belgorod State National Research University

Postgraduate student, Department of Pharmacology and Clinical Pharmacology.

Загрузки

Опубликован

30.06.2020

Как цитировать

Golubev IV, Gureev VV, Korokin MV, Zatolokina MA, Avdeeva EV, Gureeva AV, Rozhkov IS, Serdyuk EA, Soldatova VA (2020) Preclinical study of innovative peptides mimicking the tertiary structure of the α-helix B of erythropoietin. Research Results in Pharmacology 6(2): 85–96. https://doi.org/10.3897/rrpharmacology.6.55385

Выпуск

Раздел

Обзорная статья

Наиболее читаемые статьи этого автора (авторов)

1 2 > >>